Home

CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome

The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment. María Martínez, Jordi Fàbrega, Mara Dierssen, Ana Aldea, Rafael de la Torre and Ana Roche representing CONNECTA...

Continue reading

CONNECTA Therapeutics begins administration of CTH120 to the first healthy volunteers in Phase I clinical trial

Hospital del Mar Research Institute CONNECTA Therapeutics announces that the first healthy volunteers in the Phase I clinical trial of CTH120 have been administered the drug at Hospital del Mar - Hospital del Mar Research Institute in Barcelona. The study is recruiting 68 healthy individuals, both women and men aged between 18 and 55 years,...

Continue reading

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

Barcelona, 06 September 2021 CTH120, designed using artificial intelligence techniques, will start Phase I in 2022 CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases   CTH120 Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile...

Continue reading

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

Barcelona The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences   The public-private consortium formed by...

Continue reading

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

Barcelona The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme   The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from...

Continue reading